clinical trial · NCT07029555
An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis
Rheumatoid ArthritisPIT565
brief summary
The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of PIT565, in participants with rheumatoid arthritis (RA).
started
Jun 12, 2025
primary completion
May 15, 2028
completion
May 16, 2028
last updated
Jun 30, 2026
detailed description
This is an open-label, uncontrolled study in participants with RA. PIT565 will be administered subcutaneously. The objective of the study is to assess the safety of PIT565 in participants with RA.
official title
A Phase Ib, Open-label, Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of PIT565 in Participants With Rheumatoid Arthritis (RA)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol